

1
2
3 **SUSTIVA™**
4 **(efavirenz capsules)**
5 **Rx Only**
6

7 SUSTIVA (efavirenz) in combination with other antiretroviral agents is indicated for the treatment of
8 HIV-1 infection. This indication is based on analyses of plasma HIV-RNA levels and CD4 cell counts in
9 controlled studies of up to 24 weeks in duration. At present, there are no results from controlled trials
10 evaluating long-term suppression of HIV-RNA with SUSTIVA.
11

12 Resistant virus emerges rapidly when non-nucleoside reverse transcriptase inhibitors (NNRTIs) are
13 administered as monotherapy. Therefore, SUSTIVA must not be used as a single agent to treat HIV or
14 added on as a sole agent to a failing regimen. SUSTIVA therapy should always be initiated in combination
15 with at least one other antiretroviral agent to which the patient has not been previously exposed.


16
17 **DESCRIPTION**
18

19 SUSTIVA (efavirenz) is an HIV-1 specific, non-nucleoside, reverse transcriptase inhibitor (NNRTI).
20

21 SUSTIVA is available as capsules for oral administration containing either 50 mg, 100 mg, or 200 mg of
22 efavirenz and the following inactive ingredients: lactose monohydrate, magnesium stearate, sodium lauryl
23 sulfate, and sodium starch glycolate. The capsule shell contains the following inactive ingredients and
24 dyes: gelatin, sodium lauryl sulfate, titanium dioxide and/or yellow iron oxide. The capsule shells may also
25 contain silicon dioxide. The capsules are printed with ink containing carmine 40 blue, FD&C Blue No. 2
26 and titanium dioxide.
27

28 Efavirenz is chemically described as (S) -6- chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-
29 (trifluoromethyl)-2H-3,1-benzoxazin-2-one.
30

31 Its empirical formula is C₁₄H₉ClF₃NO₂ and its structural formula is:



32
33
34 Efavirenz is a white to slightly pink crystalline powder with a molecular mass of 315.68. It is practically
35 insoluble in water (<10 µg/mL).
36

37 **MICROBIOLOGY**
38

39 **Mechanism of Action:** Efavirenz is a non-nucleoside reverse transcriptase (RT) inhibitor of human
40 immunodeficiency virus type 1 (HIV-1). Efavirenz activity is mediated predominantly by non-competitive
41 inhibition of HIV-1 RT. HIV-2 RT and human cellular DNA polymerases alpha, beta, gamma, and delta
42 are not inhibited by efavirenz.
43

44 **In vitro HIV Susceptibility:** The clinical significance of *in vitro* susceptibility of HIV-1 to efavirenz has
45 not been established. The *in vitro* antiviral activity of efavirenz was assessed in lymphoblastoid cell lines,
46 peripheral blood mononuclear cells (PBMCs) and macrophage/monocyte cultures. The 90-95% inhibitory
47 concentration (IC₉₀₋₉₅) of efavirenz for wild type laboratory adapted strains and clinical isolates ranged

48 from 1.7 to 25 nM. Efavirenz demonstrated synergistic activity against HIV-1 in cell culture when
49 combined with zidovudine (ZDV), didanosine, or indinavir (IDV).

50
51 **Resistance:** HIV-1 isolates with reduced susceptibility to efavirenz (>380-fold increase in IC₉₀) compared
52 to baseline can emerge *in vitro*. Phenotypic (N=26) changes in evaluable HIV-1 isolates and genotypic
53 (N=62) changes in plasma virus from selected patients treated with efavirenz in combination with IDV, or
54 with ZDV plus lamivudine were monitored. One or more RT mutations at amino acid positions 100, 101,
55 103, 108, 190 and 225, were observed in all 62 patients with a frequency of at least 10% compared to
56 baseline. The mutation at RT amino acid position 103 (lysine to asparagine) was the most frequently
57 observed (≥90%). A mean loss in susceptibility (IC₉₀) to efavirenz of 47-fold was observed in 26 clinical
58 isolates. Five clinical isolates were evaluated for both genotypic and phenotypic changes from baseline.
59 Decreases in efavirenz susceptibility (range from 9 to >312-fold increase in IC₉₀) were observed for these
60 isolates *in vitro* compared to baseline. All 5 isolates possessed at least one of the efavirenz-associated RT
61 mutations. The clinical relevance of phenotypic and genotypic changes associated with efavirenz therapy
62 has not been established.

63
64 **Cross-Resistance:** Rapid emergence of HIV-1 strains that are cross-resistant to non-nucleoside RT
65 inhibitors has been observed *in vitro*. Thirteen clinical isolates previously characterized as efavirenz-
66 resistant were also phenotypically resistant to nevirapine and delavirdine *in vitro* compared to baseline.
67 Clinically derived ZDV-resistant HIV-1 isolates tested *in vitro* retained susceptibility to efavirenz. Cross-
68 resistance between efavirenz and HIV protease inhibitors is unlikely because of the different enzyme
69 targets involved.

70 71 **CLINICAL PHARMACOLOGY**

72 73 **Pharmacokinetics**

74 **Absorption:** Peak efavirenz plasma concentrations of 1.6-9.1 μM were attained by 5 hours following
75 single oral doses of 100 mg to 1600 mg administered to uninfected volunteers. Dose-related increases in
76 C_{max} and AUC were seen for doses up to 1600 mg; the increases were less than proportional suggesting
77 diminished absorption at higher doses.

78
79 In HIV-infected patients at steady-state, mean C_{max}, mean C_{min}, and mean AUC were dose proportional
80 following 200 mg, 400 mg, and 600 mg daily doses. Time-to-peak plasma concentrations were
81 approximately 3-5 hours and steady-state plasma concentrations were reached in 6-10 days. In 35 patients
82 receiving SUSTIVA 600 mg QD, steady-state C_{max} was 12.9 ± 3.7 μM (mean ± S.D.), steady-state C_{min}
83 was 5.6 ± 3.2 μM, and AUC was 184 ± 73 μM•h.

84
85 **Effect of Food on Oral Absorption:** In uninfected volunteers, meals of normal composition had no
86 appreciable effect on the bioavailability of 100 mg of an investigational efavirenz formulation administered
87 twice a day for 10 days with meals (Breakfast: 662 kcal, 13.8 g protein, 27.9 g fat, 94.6 g carbohydrate;
88 Dinner: 567 kcal, 44.5 g protein, 12.5 g fat, 73.8 g carbohydrate). The relative bioavailability of a single
89 1200 mg dose of an investigational efavirenz formulation in uninfected volunteers (N=5) was increased
90 50% (range 11%-126%) following a high fat meal (1070 kcal, 82 g fat, 69% of calories from fat) (see
91 **DOSAGE AND ADMINISTRATION**).

92
93 **Distribution:** Efavirenz is highly bound (approximately 99.5-99.75%) to human plasma proteins,
94 predominantly albumin. In HIV-1 infected patients (N=9) who received SUSTIVA 200 to 600 mg once
95 daily for at least one month, cerebrospinal fluid concentrations ranged from 0.26 to 1.19% (mean 0.69%) of
96 the corresponding plasma concentration. This proportion is approximately 3-fold higher than the non-
97 protein-bound (free) fraction of efavirenz in plasma.

98
99 **Metabolism:** Studies in humans and *in vitro* studies using human liver microsomes have demonstrated that
100 efavirenz is principally metabolized by the cytochrome P450 system to hydroxylated metabolites with
101 subsequent glucuronidation of these hydroxylated metabolites. These metabolites are essentially inactive
102 against HIV-1. The *in vitro* studies suggest that CYP3A4 and CYP2B6 are the major isozymes responsible
103 for efavirenz metabolism.

104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148

Efavirenz has been shown to induce P450 enzymes, resulting in the induction of its own metabolism. Multiple doses of 200-400 mg per day for 10 days resulted in a lower than predicted extent of accumulation (22-42% lower) and a shorter terminal half-life of 40-55 hours (single dose half-life 52-76 hours).

Elimination: Efavirenz has a terminal half-life of 52-76 hours after single doses and 40-55 hours after multiple doses. A one-month mass balance/excretion study was conducted using 400 mg per day with a ¹⁴C-labeled dose administered on Day 8. Approximately 14-34% of the radiolabel was recovered in the urine and 16-61% was recovered in the feces. Nearly all of the urinary excretion of the radiolabeled drug was in the form of metabolites. Efavirenz accounted for the majority of the total radioactivity measured in feces.

Special Populations

Hepatic Impairment: The pharmacokinetics of efavirenz have not been adequately studied in patients with hepatic impairment (see **PRECAUTIONS; General**).

Renal Impairment: The pharmacokinetics of efavirenz have not been studied in patients with renal insufficiency; however, less than 1% of efavirenz is excreted unchanged in the urine, so the impact of renal impairment on efavirenz elimination should be minimal.

Gender and Race: The pharmacokinetics of efavirenz in patients appear to be similar between men and women and among the racial groups studied.

Geriatric: see **PRECAUTIONS; Geriatric Use**

Pediatrics: see **PRECAUTIONS; Pediatric Use**

Drug Interactions (see also **PRECAUTIONS; Drug Interactions**)

Efavirenz has been shown *in vivo* to cause hepatic enzyme induction, thus increasing the biotransformation of some drugs metabolized by CYP3A4. *In vitro* studies have shown that efavirenz inhibited P450 isozymes 2C9, 2C19, and 3A4 with K_i values (8.5-17 μ M) in the range of observed efavirenz plasma concentrations. In *in vitro* studies, efavirenz did not inhibit CYP2E1 and inhibited CYP2D6 and CYP1A2 (K_i values 82-160 μ M) only at concentrations well above those achieved clinically. The effects on CYP3A4 activity are expected to be similar between 200 mg, 400 mg and 600 mg doses of efavirenz. Coadministration of efavirenz with drugs primarily metabolized by 2C9, 2C19 and 3A4 isozymes may result in altered plasma concentrations of the coadministered drug. Drugs which induce CYP3A4 activity would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.

Drug interaction studies were performed with efavirenz and other drugs likely to be coadministered or drugs commonly used as probes for pharmacokinetic interaction. The effects of coadministration of efavirenz on the AUC and C_{max} are summarized in Table 1 (effect of efavirenz on other drugs) and Table 2 (effect of other drugs on efavirenz). For information regarding clinical recommendations see

PRECAUTIONS; Drug Interactions.

149
150
151

Table 1
Effect of Efavirenz on Coadministered Drug Plasma C_{max} and AUC

Coadministered Drug:	Dose	Efavirenz Dose	Number of Subjects	Coadministered Drug (% change)	
				C _{max} (mean [90% CI])	AUC (mean [90% CI])
Indinavir	800 mg q8h x 14 days	200 mg x 14 days	17	↓ (16%) [-10-35%]	↓ (31%) [13-45%]
Nelfinavir	750 mg q8h x 7 days	600 mg x 7 days	10	↑ (21%) [10-33%]	↑ (20%) [8-34%]
Metabolite AG-1402				↓ (40%) [30-48%]	↓ (37%) [25-48%]
Ritonavir	500 mg q12h x 8 days After AM dose After PM dose	600 mg x 10 days	11	↑ (24%) [12-38%] ↔	↑ (18%) [6-33%] ↔
Saquinavir SGC*	1200 mg q8h x 10 days	600 mg x 10 days	12	↓ (50%) [28-66%]	↓ (62%) [45-74%]
Lamivudine	150 mg q12h x 14 days	600 mg x 14 days	9	↔	↔
Zidovudine	300 mg q12h x 14 days	600 mg x 14 days	9	↔	↔
Azithromycin	600 mg single dose	400 mg x 7 days	14	↑ (22%) [4-42%]	↔
Clarithromycin	500 mg q12h x 7 days	400 mg x 7 days	11	↓ (26%) [15-35%]	↓ (39%) [30-46%]
14-OH metabolite				↑ (49%) [32-69%]	↑ (34%) [18-53%]
Fluconazole	200 mg x 7 days	400 mg x 7 days	10	↔	↔
Ethinyl Estradiol	50 µg single dose	400 mg x 10 days	13	↔	↑ (37%) [25-51%]

↑ Indicates increase ↓ Indicates decrease ↔ Indicates no change

* Soft Gelatin Capsule

152
153
154

Table 2
Effect of Coadministered Drug on Efavirenz Plasma C_{max} and AUC

Coadministered Drug:	Dose	Efavirenz Dose	Number of Subjects	Efavirenz (% change)	
				C _{max} (mean [90% CI])	AUC (mean [90% CI])
Indinavir	800 mg q8h x 14 days	200 mg x 14 days	11	↔	↔
Nelfinavir	750 mg q8h x 7 days	600 mg x 7 days	10	↔	↔
Ritonavir	500 mg q12h x 8 days	600 mg x 10 days	9	↑ (14%) [4-26%]	↑ (21%) [10-34%]
Saquinavir SGC*	1200 mg q8h x 10 days	600 mg x 10 days	13	↓ (13%) [5-20%]	↓ (12%) [4-19%]
Rifampin	600 mg x 7 days	600 mg x 7 days	12	↓ (20%) [11-28%]	↓ (26%) [15-36%]
Azithromycin	600 mg single dose	400 mg x 7 days	14	↔	↔
Clarithromycin	500 mg q12h x 7 days	400 mg x 7 days	12	↑ (11%) [3-19%]	↔
Fluconazole	200 mg x 7 days	400 mg x 7 days	10	↔	↑ (16%) [6-26%]
Famotidine	40 mg single dose	400 mg single dose	17	↔	↔
Mylanta DS**	30 mL single dose	400 mg single dose	17	↔	↔
Ethinyl Estradiol	50 µg single dose	400 mg x 10 days	13	↔	↔

↑ Indicates increase ↓ Indicates decrease ↔ Indicates no change
 * Soft Gelatin Capsule
 ** Contains aluminum hydroxide 400 mg, magnesium hydroxide 400 mg, plus simethicone 40 mg

155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175

INDICATIONS AND USAGE

SUSTIVA (efavirenz) in combination with other antiretroviral agents is indicated for the treatment of HIV-1 infection. This indication is based on analyses of plasma HIV-RNA levels and CD4 cell counts in controlled studies of up to 24 weeks in duration. At present, there are no results from controlled trials evaluating long-term suppression of HIV-RNA with SUSTIVA.

Description of Studies

In the clinical studies described below, the primary efficacy measure was the percent of patients with plasma HIV-RNA <400 copies/mL (<500 copies/mL in ACTG 364), using the Roche RT-PCR (Amplicor™) HIV-1 Monitor assay.


In the analysis presented in each figure, patients who terminated the study early for any reason or who had a missing HIV-RNA measurement that was either preceded or followed by a measurement above the limit of assay quantification were considered to have HIV-RNA above 400 copies/mL at the missing time points.

Study 006 is an ongoing, randomized, open-label trial to evaluate the plasma HIV-RNA suppression achieved by the combination of SUSTIVA (600 mg QD) + indinavir (IDV, 1000 mg q8h) or SUSTIVA

176 (600 mg QD) + zidovudine (ZDV, 300 mg q12h) + lamivudine (LAM, 150 mg q12h) versus indinavir (800
 177 mg q8h) + zidovudine (300 mg q12h) + lamivudine (150 mg q12h). Twenty-four week data analyses are
 178 presented for 450 patients (mean age 36.3 years [range 18-64], 60% Caucasian, 86% male). Overall mean
 179 baseline CD4 count was 345 cells/mm³, and mean HIV-RNA plasma level was 4.77 log₁₀ copies/mL. The
 180 percent of patients achieving plasma HIV-RNA levels <400 copies/mL is presented in Figure 1. Through
 181 24 weeks of therapy, there was no significant difference in the mean CD4 cell count between the treatment
 182 arms; the overall mean increase was 143 cells.

183
 184

Figure 1



185
 186
 187
 188
 189
 190
 191
 192
 193
 194


Weeks In Study

More subjects on the IDV+ZDV+LAM control arm (56 subjects) discontinued the study prior to 24 weeks compared to either the SUSTIVA (efavirenz) +ZDV+LAM arm (32 subjects) or the SUSTIVA+IDV arm (35 subjects). These differences in discontinuation rates were predominantly the result of adverse events in the IDV+ZDV+LAM control arm. Subjects discontinuing from the study before 24 weeks were counted as HIV-RNA ≥400 copies/mL. Therefore, differences in discontinuations as a result of adverse events among the regimens accounted for a substantial fraction of the difference in the percent below 400 copies/mL. It is difficult to assess the relative efficacy of the treatment arms given the disproportional discontinuations in an open label study.

195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205

ACTG 364 is an ongoing 48-week double-blind, placebo-controlled study in NRTI-experienced patients who had completed two prior ACTG studies. The initial protocol-defined analysis was based on results after 16 weeks of therapy. One-hundred and ninety-six HIV-infected patients (mean age 41 years [range 18-76], 74% Caucasian, 88% male) received NRTIs in combination with SUSTIVA (600 mg QD), or nelfinavir (NFV, 750 mg TID), or SUSTIVA (600 mg QD) + nelfinavir in a randomized double-blinded manner. Upon entry into the study, all patients were assigned a new open label NRTI regimen, which was dependent on their previous NRTI treatment experience. The percent of patients achieving plasma HIV-RNA levels <500 copies/mL at the time of a preliminary non-protocol specified analysis at 24 weeks is presented in Figure 2. Through 24 weeks of therapy, there was no significant difference in the mean CD4 cell count between the treatment arms; the overall mean increase was 65 cells.


206 **Figure 2**
207



208
209
210
211
212
213
214
215
216
217
218
219
220
221

Study 020 is an ongoing, randomized, double-blind, placebo-controlled 24-week study in NRTI-experienced, protease inhibitor and NNRTI-naive patients designed to compare therapy consisting of SUSTIVA + indinavir + nucleoside analogue reverse transcriptase inhibitors versus therapy consisting of indinavir + NRTIs at 24 weeks of treatment. Patients were randomized to receive either SUSTIVA (600 mg QD) + indinavir (1000 mg q8h) + NRTIs or indinavir (800 mg q8h) + NRTIs. Sixty-eight percent of the 282 patients (mean age 38.9 years [range 22-69], 53% Caucasian, 83% male) changed their NRTI regimen at study initiation. Mean baseline CD4 count was 330 cells/mm³, and mean HIV-RNA plasma level was 4.39 log₁₀ copies/mL. Data on 282/330 patients who completed 24 weeks of treatment and achieved plasma HIV-RNA levels <400 copies/mL is presented in Figure 3. Through 24 weeks of therapy, there was no significant difference in the mean CD4 cell count between the treatment arms; the overall mean increase was 110 cells.

Study 020
Viral RNA - Proportion Below 400 Copies/mL in Plasma*



*There was no significant difference between the two treatment arms in the percent of patients achieving plasma HIV-RNA levels <400 copies/mL at 24 weeks.

CONTRAINDICATIONS

SUSTIVA is contraindicated in patients with clinically significant hypersensitivity to any of its components.

WARNINGS

Resistant virus emerges rapidly when NNRTIs are administered as monotherapy. Therefore, SUSTIVA must not be used as a single agent to treat HIV or added on as a sole agent to a failing regimen. SUSTIVA therapy should always be initiated in combination with at least one other new antiretroviral agent to which the patient has not been previously exposed.

Malformations have been observed in fetuses from efavirenz-treated monkeys that received doses which resulted in plasma drug concentrations similar to those in humans given 600 mg/day (see **PRECAUTIONS; Pregnancy**); therefore, pregnancy should be avoided in women receiving SUSTIVA. Barrier contraception should always be used in combination with other methods of contraception (e.g., oral or other hormonal contraceptives). Women of childbearing potential should undergo pregnancy testing prior to initiation of SUSTIVA.

SUSTIVA should not be administered concurrently with astemizole, cisapride, midazolam, triazolam, or ergot derivatives because competition for CYP3A4 by efavirenz could result in inhibition of metabolism of these drugs and create the potential for serious and/or life-threatening adverse events (e.g., cardiac arrhythmias, prolonged sedation or respiratory depression).

254 **PRECAUTIONS**

255

256 **General**

257

258 **Nervous System Symptoms:** There have been reports (approximately 1-2 per thousand SUSTIVA-treated
259 patients) of delusions and inappropriate behavior, predominantly in patients with a history of mental illness
260 or substance abuse. Severe acute depression (including suicidal ideation/attempts) has also been
261 infrequently reported in both SUSTIVA-treated and control-treated patients. Patients who experience these
262 symptoms should contact their doctor immediately because discontinuation of SUSTIVA may be required.

263

264 Fifty-two percent of patients receiving SUSTIVA reported central nervous system and psychiatric
265 symptoms. These symptoms included, but were not limited to, dizziness, impaired concentration,
266 somnolence, abnormal dreams and insomnia. In controlled trials, these symptoms were severe in 2.6% of
267 patients receiving SUSTIVA 600 mg QD and in 1.4% of patients receiving control regimens. In clinical
268 trials, 2.6% of SUSTIVA-treated patients discontinued therapy because of nervous system symptoms.
269 These symptoms usually begin during the first or second day of therapy and generally resolve after the first
270 2-4 weeks. Patients should be informed that these symptoms are likely to improve with continued therapy.
271 Dosing at bedtime improves the tolerability of these symptoms and is recommended during the first weeks
272 of therapy and in patients who continue to experience these symptoms (see **ADVERSE REACTIONS**).

273

274 Patients receiving SUSTIVA should be alerted to the potential for additive central nervous system effects
275 when SUSTIVA is used concomitantly with alcohol or psychoactive drugs.

276

277 Patients should be informed that SUSTIVA may cause dizziness, impaired concentration, and/or
278 drowsiness. Patients should be instructed that if they experience these symptoms they should avoid
279 potentially hazardous tasks such as driving or operating machinery.

280

281 **Skin Rash:** In controlled clinical trials, 27% (124/455) of patients treated with 600 mg SUSTIVA
282 experienced new onset skin rash compared with 17% (61/351) of patients treated in control groups. Rash
283 associated with blistering, moist desquamation, or ulceration occurred in 1% (3/455) of patients treated
284 with SUSTIVA. In all studies and expanded access, one adult developed erythema multiforme and another
285 Stevens-Johnson Syndrome among approximately 2200 treated patients. The median time to onset of rash
286 in adults was 11 days and the median duration, 14 days. The discontinuation rate for rash in clinical trials
287 was 1.7% (8/455). SUSTIVA should be discontinued in patients developing severe rash associated with
288 blistering, desquamation, mucosal involvement or fever. Appropriate antihistamines and/or corticosteroids
289 may improve the tolerability and hasten the resolution of rash.

290

291 Rash was reported in 23 of 57 pediatric patients (40%) treated with SUSTIVA. Two pediatric patients
292 experienced Grade 3 rash (one confluent rash with fever; one urticaria), and two patients had Grade 4 rash
293 (erythema multiforme). The median time to onset of rash in children was eight days. Prophylaxis with
294 appropriate antihistamines prior to initiating therapy with SUSTIVA in children should be considered (see
295 **ADVERSE REACTIONS**).

296

297 **Liver Enzymes:** In patients with known or suspected history of Hepatitis B or C infection and in patients
298 treated with other medications associated with liver toxicity, monitoring of liver enzymes is recommended.
299 In patients with persistent elevations of serum transaminases to greater than 5 times the upper limit of the
300 normal range, the benefit of continued therapy with SUSTIVA needs to be weighed against the unknown
301 risks of significant liver toxicity (see **ADVERSE REACTIONS; Laboratory Abnormalities**).

302

303 Because of the extensive cytochrome P450-mediated metabolism of efavirenz and limited clinical
304 experience in patients with hepatic impairment, caution should be exercised in administering SUSTIVA to
305 these patients.

306

307 **Cholesterol:** Monitoring of cholesterol should be considered in patients treated with SUSTIVA (see
308 **ADVERSE REACTIONS**).

309

310 **Information for Patients**

311

312 Patients should be informed that SUSTIVA is not a cure for HIV infection and that they may continue to
313 develop opportunistic infections and other complications associated with HIV disease. The long-term
314 effects of SUSTIVA (efavirenz) are unknown at this time. Patients should be told that there are currently
315 no data demonstrating that SUSTIVA therapy can reduce the risk of transmitting HIV to others through
316 sexual contact or blood contamination.

317

318 Patients should be advised to take SUSTIVA every day as prescribed. SUSTIVA must always be used in
319 combination with other antiretroviral drugs. Patients should not alter the dose or discontinue therapy
320 without consulting their physician.

321

322 Patients should be informed that central nervous system symptoms occur in approximately half the patients
323 taking SUSTIVA and that SUSTIVA may cause dizziness, impaired concentration, delusions, depression
324 and/or drowsiness. These symptoms are likely to improve with continued therapy. Dosing at bedtime
325 improves the tolerability of these symptoms and is recommended during the first weeks of therapy and in
326 patients who continue to experience these symptoms. Patients receiving SUSTIVA should be alerted to the
327 potential for additive central nervous system effects when SUSTIVA is used concomitantly with alcohol or
328 psychoactive drugs. Patients should be instructed that if they experience these symptoms they should avoid
329 potentially hazardous tasks such as driving or operating machinery.

330

331 Patients should be informed that one of the most common side effects is rash. These rashes usually go
332 away without any change in treatment. In a small number of patients, rash may be serious. Patients should
333 be advised that they should contact their physician promptly if they develop a rash.

334

335 Because malformations have been observed in fetuses from efavirenz-treated animals, instructions should
336 be given to avoid pregnancy in women receiving SUSTIVA. Women should be advised to notify their
337 physician if they become pregnant while taking SUSTIVA. A reliable form of barrier contraception should
338 always be used in combination with other methods of contraception, including oral or other hormonal
339 contraception because the effects of efavirenz on hormonal contraceptives are not fully characterized.

340

341 SUSTIVA may interact with some drugs; therefore, patients should be advised to report the use of any
342 prescription or non-prescription medication to their physician.

343

344 High fat meals may increase the absorption of SUSTIVA and should be avoided. SUSTIVA may be taken
345 with meals of normal fat content (see **CLINICAL PHARMACOLOGY; Effect of Food on Oral**
346 **Absorption**).

347

348 **Drug Interactions (see also CLINICAL PHARMACOLOGY; Drug Interactions)**

349

350 Efavirenz has been shown *in vivo* to induce CYP3A4. Other compounds that are substrates of CYP3A4
351 may have decreased plasma concentrations when coadministered with SUSTIVA. *In vitro* studies have
352 demonstrated that efavirenz inhibits 2C9, 2C19 and 3A4 isozymes in the range of observed efavirenz
353 plasma concentrations. Coadministration of efavirenz with drugs primarily metabolized by these isozymes
354 may result in altered plasma concentrations of the coadministered drug. Therefore, appropriate dose
355 adjustments may be necessary for these drugs.

356

357 Drugs which induce CYP3A4 activity (e.g., phenobarbital, rifampin, rifabutin) would be expected to
358 increase the clearance of efavirenz resulting in lowered plasma concentrations. Drug interactions with
359 SUSTIVA are summarized in Table 3.

360

361 **Table 3***

362

Drugs That Should Not Be Coadministered With SUSTIVA

Drug Class	Drugs Within Class Not To Be Coadministered With SUSTIVA
Antihistamines	astemizole

Benzodiazepines	midazolam, triazolam
GI Motility Agents	cisapride
Anti-Migraine	ergot derivatives

363 **Drugs That Require A Dose Adjustment When Coadministered With SUSTIVA**

Drug Class	Drug Within Class Requiring Dose Increase
Anti-HIV Protease Inhibitor	indinavir (increase dose from 800 mg to 1000 mg every 8 hours)

364 **Other Potentially Clinically Significant Drug Interactions With SUSTIVA**

Anticoagulants: Warfarin	Plasma concentrations and effects potentially increased or decreased by SUSTIVA
Anti-HIV Protease Inhibitor: Saquinavir	Plasma concentrations decreased by SUSTIVA; should not be used as sole protease inhibitor in combination with SUSTIVA
Antimycobacterial Agents Clarithromycin Rifabutin Rifampin	Plasma concentrations decreased by SUSTIVA; clinical significance unknown Effects unknown Decreases efavirenz plasma concentrations; clinical significance unknown
Estrogens: Ethinyl Estradiol	Plasma concentrations increased by SUSTIVA; clinical significance unknown

365 * See Tables 1 and 2.

366

367 **Concomitant Antiretroviral Agents:**

368 Nelfinavir: The AUC and C_{max} of nelfinavir (750 mg q8h) are increased by 20% and 21%, respectively
369 when given with SUSTIVA in uninfected volunteers. No dose adjustment is necessary when nelfinavir is
370 administered in combination with SUSTIVA.

371

372 Indinavir: When indinavir (800 mg every 8 hours) was given with SUSTIVA, the indinavir AUC and C_{max}
373 were decreased by approximately 31% and 16%, respectively as a result of enzyme induction. Therefore,
374 the dose of indinavir should be increased from 800 mg to 1000 mg every 8 hours when SUSTIVA and
375 indinavir are coadministered. No adjustment of the dose of SUSTIVA is necessary when given with
376 indinavir.

377

378 Ritonavir: When SUSTIVA and ritonavir 500 mg (given every 12 hours) were studied in uninfected
379 volunteers, the AUC for each drug was increased by approximately 20%. The combination was associated
380 with a higher frequency of adverse clinical experiences (e.g., dizziness, nausea, paresthesia) and laboratory
381 abnormalities (elevated liver enzymes). Monitoring of liver enzymes is recommended when SUSTIVA is
382 used in combination with ritonavir.

383

384 Saquinavir: When saquinavir soft gelatin capsules (1200 mg q8h) were given with SUSTIVA to uninfected
385 volunteers, saquinavir AUC and C_{max} were decreased by 62% and 50%, respectively. Use of SUSTIVA in
386 combination with saquinavir as the sole protease inhibitor is not recommended.

387

388 Saquinavir/Ritonavir: No pharmacokinetic data are available on the potential interactions of SUSTIVA
389 with the combination of saquinavir and ritonavir.

390

391 Nucleoside Analogue Reverse Transcriptase Inhibitors: Studies of the interaction between SUSTIVA and
392 the combination of zidovudine (300 mg q12h) and lamivudine (150 mg q12h) were performed in HIV-
393 infected patients. No clinically significant pharmacokinetic interactions were observed. Specific drug
394 interaction studies have not been performed with SUSTIVA and other NRTIs. Clinically significant
395 interactions would not be expected since the NRTIs are metabolized via a different route than efavirenz and
396 would be unlikely to compete for the same metabolic enzymes and elimination pathways.
397

398 Non-Nucleoside Reverse Transcriptase Inhibitors: No studies have been performed with SUSTIVA in
399 combination with other NNRTIs.

400

401 ***Antimicrobial Agents:***

402 Rifamycins: Rifampin (600 mg daily) reduced efavirenz AUC by 26% and C_{max} by 20% in 12 uninfected
403 volunteers. Adjustment of the dose of SUSTIVA when taken with rifampin is not recommended; however,
404 the clinical significance of the reduced efavirenz levels is not known. No dose adjustment of rifampin is
405 recommended when given with SUSTIVA. Rifabutin has not been studied in combination with SUSTIVA;
406 however, there is a potential for an interaction.

407

408 Macrolide Antibiotics:

409 Azithromycin: Coadministration of single 600 mg doses of azithromycin and multiple doses of SUSTIVA
410 in uninfected volunteers did not result in any clinically significant pharmacokinetic interaction. No dosage
411 adjustment is necessary when azithromycin is given in combination with SUSTIVA.

412

413 Clarithromycin: Coadministration of SUSTIVA with clarithromycin given as 500 mg every 12 hours for
414 seven days resulted in a significant effect of efavirenz on the pharmacokinetics of clarithromycin. The
415 AUC and C_{max} of clarithromycin decreased 39% and 26%, respectively, while the AUC and C_{max} of the
416 clarithromycin hydroxymetabolite were increased 34% and 49%, respectively, when used in combination
417 with SUSTIVA. The clinical significance of these changes in clarithromycin plasma levels is not known. In
418 uninfected volunteers, 46% developed rash while receiving SUSTIVA and clarithromycin. No dose
419 adjustment of SUSTIVA is recommended when given with clarithromycin. Alternatives to clarithromycin,
420 such as azithromycin, should be considered.

421

422 Other macrolide antibiotics, such as erythromycin, have not been studied in combination with SUSTIVA.

423

424 ***Antifungal Agents:***

425 No clinically significant pharmacokinetic interactions were seen when fluconazole (200 mg daily) and
426 SUSTIVA were coadministered to uninfected volunteers. No dosage adjustment is necessary when the two
427 drugs are used in combination. The potential for drug interactions with SUSTIVA and other imidazole and
428 triazole antifungals, such as itraconazole and ketoconazole, has not been studied.

429

430 ***Other Drug Interactions:***

431 Antacids/famotidine: Neither aluminum/magnesium hydroxide antacids (30 mL single dose) nor famotidine
432 (40 mg single dose) altered the absorption of efavirenz in uninfected volunteers. These data suggest that
433 alteration of gastric pH by other drugs would not be expected to affect efavirenz absorption.

434

435 Oral Contraceptives (ethinyl estradiol): Only the ethinyl estradiol component of oral contraceptives has
436 been studied in combination with SUSTIVA. The AUC following a single dose of 50 µg ethinyl estradiol
437 was increased (37%) by efavirenz. No significant changes were observed in C_{max} of ethinyl estradiol. The
438 clinical significance of these effects is not known. No effect of a single dose of ethinyl estradiol on
439 efavirenz C_{max} or AUC was observed. Because the potential interaction of efavirenz with oral
440 contraceptives has not been fully characterized, a reliable method of barrier contraception should be used in
441 addition to oral contraceptives.

442

443 ***Carcinogenesis, Mutagenesis and Impairment of Fertility:***

444 Long-term carcinogenicity studies of efavirenz in rats and mice are in progress.

445

446 Efavirenz was not mutagenic or genotoxic in *in vitro* and *in vivo* genotoxicity assays which included
447 bacterial mutation assays in *S. typhimurium* and *E. coli*, mammalian mutation assays in Chinese Hamster
448 Ovary cells, chromosomal aberration assays in human peripheral blood lymphocytes or Chinese Hamster
449 Ovary cells, and an *in vivo* mouse bone marrow micronucleus assay.

450

451 Efavirenz did not impair mating or fertility of male or female rats, and did not affect sperm of treated male
452 rats. The reproductive performance of offspring born to female rats given efavirenz was not affected. As a
453 result of the rapid clearance of efavirenz in rats, systemic drug exposures achieved in these studies were
454 equivalent to or below those achieved in humans given therapeutic doses of efavirenz.

455

456 ***Pregnancy:***

457 Pregnancy Category C: Malformations have been observed in 3 of 20 fetuses/infants from efavirenz-
458 treated cynomolgus monkeys (versus 0 of 20 concomitant controls) in a developmental toxicity study. The
459 pregnant monkeys were dosed throughout pregnancy (post coital days 20-150) with efavirenz 60 mg/kg
460 daily, a dose which resulted in plasma drug concentrations similar to those in humans given 600 mg/day of
461 SUSTIVA. Anencephaly and unilateral anophthalmia were observed in one fetus, microphthalmia was
462 observed in another fetus, and cleft palate was observed in a third fetus. Efavirenz crosses the placenta in
463 cynomolgus monkeys and produces fetal blood concentrations similar to maternal blood concentrations.
464 Because teratogenic effects have been seen in primates at efavirenz exposures similar to those seen in the
465 clinic at the recommended dose, pregnancy should be avoided in women receiving SUSTIVA. Barrier
466 contraception should always be used in combination with other methods of contraception (e.g., oral or other
467 hormonal contraceptives). Women of childbearing potential should undergo pregnancy testing prior to
468 initiation of SUSTIVA (see **WARNINGS**).

469

470 Efavirenz has been shown to cross the placenta in rats and rabbits and produces fetal blood concentrations
471 of efavirenz similar to maternal concentrations. An increase in fetal resorptions was observed in rats at
472 efavirenz doses that produced peak plasma concentrations and AUC values in female rats equivalent to, or
473 lower than those achieved in humans given 600 mg QD of SUSTIVA (efavirenz). Efavirenz produced no
474 reproductive toxicities when given to pregnant rabbits at doses that produced peak plasma concentrations
475 similar to, and AUC values approximately half of those achieved in humans given 600 mg QD of
476 SUSTIVA.

477

478 There are no adequate and well-controlled studies in pregnant women. SUSTIVA should be used during
479 pregnancy only if the potential benefit justifies the potential risk to the fetus, such as in pregnant women
480 without other therapeutic options.

481

482 **Antiretroviral Pregnancy Registry:** To monitor fetal outcomes of pregnant women exposed to
483 SUSTIVA, an Antiretroviral Pregnancy Registry has been established. Physicians are encouraged to
484 register patients by calling (800) 258-4263.

485

486 ***Nursing Mothers:***

487 The Centers for Disease Control and Prevention recommend that HIV-infected mothers not breast-feed
488 their infants to avoid risking postnatal transmission of HIV infection. Studies in rats have demonstrated that
489 efavirenz is excreted in milk. Mothers should be instructed not to breast-feed if they are receiving
490 SUSTIVA.

491

492 **Pediatric Use:**

493 ACTG 382 is an ongoing open-label 48-week study in 57 NRTI-experienced pediatric patients to
494 characterize the safety, pharmacokinetics, and antiviral activity of SUSTIVA in combination with
495 nelfinavir (20-30 mg/kg TID) and NRTIs. Mean age was 8 years (range 3-16). SUSTIVA has not been
496 studied in pediatric patients below 3 years of age or who weigh less than 13 Kg. The type and frequency of
497 adverse experiences was generally similar to that of adult patients with the exception of a higher incidence
498 of rash which was reported in 40% (23/57) of pediatric patients compared to 28% of adults, and a higher
499 frequency of Grade 3 or 4 rash reported in 7% (4/57) of pediatric patients compared to 0.7% of adults (see
500 **ADVERSE REACTIONS; Table 5).**

501

502 The starting dose of SUSTIVA was 600 mg QD adjusted to body size, based on weight, targeting AUC
503 levels in the range of 190-380 µM•h. The pharmacokinetics of efavirenz in pediatric patients were similar
504 to the pharmacokinetics in adults who received 600 mg daily doses of SUSTIVA. In 48 pediatric patients
505 receiving the equivalent of a 600 mg dose of SUSTIVA, steady-state C_{max} was 14.2± 5.8 µM (mean ± S.D.),
506 steady-state C_{min} was 5.6 ± 4.1 µM, and AUC was 218 ± 104 µM•h.

507

508 **Geriatric Use:**

509 Clinical studies of SUSTIVA did not include sufficient numbers of subjects aged 65 and over to determine
510 whether they respond differently from younger subjects.

511

512 **ADVERSE REACTIONS**

513

514 SUSTIVA has been studied in 2215 patients. The most significant adverse events associated with
515 SUSTIVA therapy are nervous system symptoms and rash.

516

517 **Nervous System Symptoms:** Fifty-two percent of patients receiving SUSTIVA reported central nervous
518 system and psychiatric symptoms. Table 4 lists the frequency of symptoms of different degrees of
519 severity, and gives the discontinuation rates, in clinical trials for the central nervous system symptom of
520 dizziness or for one or more of the following psychiatric symptoms: somnolence, insomnia, abnormal
521 dreaming, confusion, abnormal thinking, impaired concentration, amnesia, agitation, depersonalization,
522 hallucinations and euphoria. The frequencies of specific central and peripheral nervous system symptoms
523 and psychiatric symptoms are provided in Table 6 (see **PRECAUTIONS; General**).

524

525 **Table 4**

526 **Percent of Patients with One or More Selected Nervous System Symptoms^{1,2}**

Percent of Patients with:	SUSTIVA 600 mg QD (N=455)	Control Groups (N=351)
	%	%
Mild Symptoms ³	31.4	16.5
Moderate Symptoms ⁴	17.8	8.0
Severe Symptoms ⁵	2.6	1.4
Symptoms of Any Severity	51.9	25.9
Treatment discontinuation as a result of symptoms	2.6	0.6

527

528

529

530

531

532

533 **Skin Rash:** Rashes are usually mild-to-moderate maculopapular skin eruptions that occur within the first
534 two weeks of initiating therapy with SUSTIVA. In most patients, rash resolves with continuing SUSTIVA
535 therapy within one month. SUSTIVA can be reinitiated in patients interrupting therapy because of rash. Use
536 of appropriate antihistamines and/or corticosteroids is recommended when SUSTIVA is restarted.
537 SUSTIVA should be discontinued in patients developing severe rash associated with blistering,
538 desquamation, mucosal involvement or fever. The frequency of rash by NCI grade and the discontinuation
539 rates as a result of rash are provided in Table 5.

540

541 **Table 5**

542 **Percent of Patients with Treatment-Emergent Rash^{1,2}**

Percent of Patients with:	Description of Rash Grade ³	SUSTIVA 600 mg QD Adults (N=455)	SUSTIVA Children (N=57)	Control Groups Adults (N=351)
		%	%	%
Grade 1 Rash	Erythema, pruritus	9.9	8.8	9.4
Grade 2 Rash	Diffuse maculopapular rash, dry desquamation	16.7	24.5	8.0
Grade 3 Rash	Vesiculation, moist desquamation, ulceration	0.7	3.5	0.0
Grade 4 Rash	Erythema multiforme, Stevens-Johnson Syndrome, toxic epidermal necrolysis, necrosis requiring surgery, exfoliative dermatitis	0.0	3.5	0.0
Rash of Any Grade	-	27.3	40.3	17.3
Treatment discontinuation as a result of rash	-	1.7	8.8	0.3

543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558

1. Includes events reported regardless of causality.
2. Data from Studies 006, 020, and two Phase 2 studies.
3. NCI Grading System.

As seen in Table 5, rash is more common in children and more often of higher grade (i.e., more severe) (see **PRECAUTIONS; General**).

Experience with SUSTIVA in patients who discontinued other antiretroviral agents of the NNRTI class is limited. Nineteen patients who discontinued nevirapine because of rash have been treated with SUSTIVA. Nine of these patients developed mild-to-moderate rash while receiving therapy with SUSTIVA, and two of these patients discontinued because of rash.

Drug-related clinical adverse experiences of moderate or severe intensity observed in $\geq 2\%$ of patients in three controlled clinical trials are presented in Table 6.

559
560
561
562

Table 6
Percent of Patients with Treatment-Emergent¹ Adverse Events of Moderate or Severe Intensity
Reported in ≥2% of Patients in Studies 006, ACTG 364, and 020

Adverse Events	Study 006 LAM, NNRTI and Protease Inhibitor Naive Patients			Study ACTG 364 NRTI-experienced NNRTI and Protease Inhibitor Naive Patients			Study 020 NRTI-experienced NNRTI and Protease Inhibitor Naive Patients	
	SUSTIVA ² + ZDV/LAM (N=148) %	SUSTIVA ² + Indinavir (N=141) %	Indinavir + ZDV/LAM (N=142) %	SUSTIVA ² + Nelfinavir + NRTIs (N=64) %	SUSTIVA ² + NRTIs (N=65) %	Nelfinavir + NRTIs (N=66) %	SUSTIVA ² + Indinavir + NRTIs (N=134) %	Indinavir + NRTIs (N=144) %
Body as a Whole								
Fatigue	7	6	10	0	2	3	5	1
Central and Peripheral Nervous System								
Dizziness	10	6	1	2	5	0	8	1
Headache	6	6	5	5	0	2	6	4
Hypoesthesia	1	1	0	2	2	0	1	1
Gastrointestinal								
Nausea	12	6	25	0	2	0	11	10
Vomiting	7	3	16	--	--	--	6	6
Diarrhea	5	8	8	11	2	5	12	3
Dyspepsia	1	4	6	0	0	2	3	1
Abdominal Pain	1	1	4	0	0	2	3	1
Flatulence	1	1	2	0	0	0	0	1
Psychiatric								
Concentration Impaired	9	1	1	0	0	0	4	1
Insomnia	7	6	3	0	0	2	1	1
Abnormal Dreams	4	0	0	--	--	--	2	1
Somnolence	3	2	4	0	0	0	2	2
Depression	2	3	0	0	0	3	2	0
Anorexia	2	0	1	0	2	0	5	1
Nervousness	2	2	0	0	0	0	1	0
Skin & Appendages								
Rash	11	20	6	8	5	11	10	7
Pruritus	1	0	1	0	2	5	2	1
Increased Sweating	2	1	1	0	0	0	1	0
Urinary System Disorders								
Renal Calculus	0	1	4	0	0	0	1	3
Hematuria	1	0	4	--	--	--	0	1

563
564
565
566
567

1. Includes adverse events at least possibly related to study drug or of unknown relationship for Studies 006 and 020. Includes all adverse events regardless of relationship to study drug for Study ACTG 364.

2. SUSTIVA provided as 600 mg QD.

-- = Not Specified.

568
569
570
571
572
573

Clinical adverse experiences of moderate to severe intensity observed in ≥ 10% of 57 pediatric patients aged 3 to 16 years who received SUSTIVA (efavirenz), nelfinavir, and one or more NRTIs were: rash (40%), diarrhea/loose stools (39%), fever (26%), cough (25%), and nausea/vomiting (16%). The incidence of nervous system symptoms was 9% (5/57). Two patients experienced Grade 3 rash, two patients had Grade 4 rash, and five patients (9%) discontinued because of rash (see also **PRECAUTIONS; Pediatric Use**).

574
575
576
577
578
579

Adverse clinical experiences of moderate to severe intensity observed in less than 2% of patients receiving SUSTIVA in all Phase II/III studies, including the North American expanded access program, and considered at least possibly related or of unknown relationship to treatment and of at least moderate severity are listed below by body system:

580
581

Body as a Whole: alcohol intolerance, allergic reaction, asthenia, fever, hot flushes, malaise, pain, peripheral edema, syncope

582 *Central and Peripheral Nervous System:* ataxia, confusion, convulsions, impaired coordination, migraine
583 headaches, neuralgia, paresthesia, peripheral neuropathy, speech disorder, tremor, vertigo

584 *Gastrointestinal:* dry mouth, pancreatitis

585 *Hearing and Vestibular:* tinnitus

586 *Cardiovascular:* flushing, palpitations, tachycardia, thrombophlebitis

587 *Liver and Biliary System:* hepatitis

588 *Musculoskeletal:* arthralgia, myalgia

589 *Psychiatric:* aggravated depression, agitation, amnesia, anxiety, apathy, emotional lability, euphoria,
590 hallucination, psychosis

591 *Respiratory:* asthma

592 *Skin and Appendages:* alopecia, eczema, folliculitis, skin exfoliation, urticaria

593 *Special Senses:* abnormal vision, diplopia, parosmia, taste perversion

594

595 **Laboratory Abnormalities:**

596

597 Liver Enzymes: Among 393 patients treated with 600 mg of SUSTIVA in controlled clinical trials, 2%
598 developed AST levels and 3% developed ALT levels greater than five times the upper limit of normal.
599 Among 250 patients treated with control regimens, similar elevations of AST or ALT were seen in 3% and
600 2%, respectively.

601

602 Liver function tests should be monitored in patients with a prior history of Hepatitis B and/or C. In 53
603 patients treated with 600 mg of SUSTIVA who were seropositive for Hepatitis B and/or C, 6% developed
604 AST levels and 13% developed ALT levels greater than five times the upper limit of normal. In 41 patients
605 seropositive for Hepatitis B and/or C treated with control regimens, 5% developed AST elevations and 2%
606 developed ALT elevations to these levels. Elevations of GGT to greater than five times the upper limit of
607 the normal range were observed in 4% of all patients treated with 600 mg of SUSTIVA and in 11% of
608 patients seropositive for Hepatitis B or C. In patients treated with control regimens, the incidence of GGT
609 elevations to this level was 2%, irrespective of Hepatitis B or C serology. Isolated elevations of GGT in
610 patients receiving SUSTIVA may reflect enzyme induction not associated with liver toxicity (see
611 **PRECAUTIONS; General**).

612

613 Lipids: Increases in total cholesterol of 10-20% have been observed in some uninfected volunteers
614 receiving SUSTIVA. Modest elevations of serum triglycerides and cholesterol have also been observed in
615 non-fasting patients receiving SUSTIVA, however, the significance of these findings is unknown. The
616 effect of SUSTIVA on total, LDL, and HDL cholesterol in patients receiving therapy with SUSTIVA has
617 not been well-characterized (see **PRECAUTIONS; General**).

618

619 Cannabinoid Test Interaction: Efavirenz does not bind to cannabinoid receptors. False positive urine
620 cannabinoid test results have been reported in uninfected volunteers who received SUSTIVA. False
621 positive test results have only been observed with the CEDIA DAU Multi-Level THC assay, which is used
622 for screening, and have not been observed with other cannabinoid assays tested including tests used for
623 confirmation of positive results.

624

625

626 **OVERDOSAGE**

627

628 Some patients accidentally taking 600 mg twice daily have reported increased nervous system symptoms.
629 One patient experienced involuntary muscle contractions.

630

631 Treatment of overdose with SUSTIVA should consist of general supportive measures, including monitoring
632 of vital signs and observation of the patient's clinical status. Administration of activated charcoal may be

680 SUSTIVA capsules should be stored at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see
681 USP Controlled Room Temperature].

682

683

684

685 **DuPont Pharmaceuticals**

686 Wilmington, DE 19880

687

688 SUSTIVA™ is a trademark of DuPont Pharmaceuticals Company.

689 Printed in U.S.A.

Copyright © DuPont Pharmaceuticals Company 1998

690

691

692 6495-00/September, 1998